Literature DB >> 31739430

Interaction of the p.Q141K Variant of the ABCG2 Gene with Clinical Data and Cytokine Levels in Primary Hyperuricemia and Gout.

Veronika Horváthová1,2, Jana Bohatá1,3, Markéta Pavlíková4, Kateřina Pavelcová1,3, Karel Pavelka1,3, Ladislav Šenolt1,3, Blanka Stibůrková1,3,5.   

Abstract

Gout is an inflammatory arthritis influenced by environmental risk factors and genetic variants. The common dysfunctional p.Q141K allele of the ABCG2 gene affects gout development. We sought after the possible association between the p.Q141K variant and gout risk factors, biochemical, and clinical determinants in hyperuricemic, gouty, and acute gouty arthritis cohorts. Further, we studied the correlation of p.Q141K allele and levels of pro-/anti-inflammatory cytokines. Coding regions of the ABCG2 gene were analyzed in 70 primary hyperuricemic, 182 gout patients, and 132 normouricemic individuals. Their genotypes were compared with demographic and clinical parameters. Plasma levels of 27 cytokines were determined using a human multiplex cytokine assay. The p.Q141K variant was observed in younger hyperuricemic/gout individuals (p = 0.0003), which was associated with earlier disease onset (p = 0.004), trend toward lower BMI (p = 0.056), and C-reactive protein (CRP, p = 0.007) but a higher glomerular filtration rate (GFR, p = 0.035). Levels of 19 cytokines were higher, mainly in patients with acute gouty arthritis (p < 0.001), irrespective of the presence of the p.Q141K variant. The p.Q141K variant influences the age of onset of primary hyperuricemia or gout and other disease-linked risk factors and symptoms. There was no association with cytokine levels in the circulation.

Entities:  

Keywords:  ABCG2; acute gouty arthritis; cytokines; gout; hyperuricemia; p.Q141K

Year:  2019        PMID: 31739430     DOI: 10.3390/jcm8111965

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  4 in total

1.  Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats.

Authors:  Yanzuo Le; Xie Zhou; Jiawen Zheng; Fangmiao Yu; Yunping Tang; Zuisu Yang; Guofang Ding; Yan Chen
Journal:  Mar Drugs       Date:  2020-12-01       Impact factor: 5.118

2.  Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.

Authors:  Yu Toyoda; Kateřina Pavelcová; Jana Bohatá; Pavel Ješina; Yu Kubota; Hiroshi Suzuki; Tappei Takada; Blanka Stiburkova
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

3.  Functional Characterization of Rare Variants in OAT1/SLC22A6 and OAT3/SLC22A8 Urate Transporters Identified in a Gout and Hyperuricemia Cohort.

Authors:  Jiří Vávra; Andrea Mančíková; Kateřina Pavelcová; Lenka Hasíková; Jana Bohatá; Blanka Stibůrková
Journal:  Cells       Date:  2022-03-22       Impact factor: 6.600

4.  Circulating microRNA alternations in primary hyperuricemia and gout.

Authors:  Jana Bohatá; Veronika Horváthová; Markéta Pavlíková; Blanka Stibůrková
Journal:  Arthritis Res Ther       Date:  2021-07-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.